Biotech Stock Gets Booted in Latest Fund Update

Nuvalent’s primary focus is on advancing targeted therapies for patients with cancers driven by specific genetic mutations, aiming to address unmet medical needs in oncology.The company operates a biotechnology business model, focusing on research and development of novel small molecule inhibitors for oncology.Nuvalent develops clinical-stage therapies targeting cancer, with lead candidates NVL-520 (a ROS1-selective inhibitor) and NVL-655 (an ALK-selective inhibitor), both designed to address resistance and ...